HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toshiyuki Yoneda Selected Research

Receptor Activator of Nuclear Factor-kappa B (TRANCE-R)

6/2016Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.
12/2012[Treatment of bone metastasis by denosumab, the human monoclonal neutralizing antibody to RANKL].
1/2008Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice.
8/2004Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Toshiyuki Yoneda Research Topics

Disease

50Neoplasms (Cancer)
01/2022 - 02/2002
41Neoplasm Metastasis (Metastasis)
10/2021 - 02/2002
24Breast Neoplasms (Breast Cancer)
01/2022 - 02/2002
23Bone Resorption
01/2017 - 03/2002
11Pain (Aches)
02/2021 - 04/2006
7Rheumatoid Arthritis
11/2021 - 05/2011
6Osteoporosis
12/2018 - 07/2010
5Acidosis
12/2018 - 04/2006
5Multiple Myeloma
01/2017 - 10/2004
5Bone Diseases (Bone Disease)
03/2016 - 03/2004
4Hypercalcemia (Milk Alkali Syndrome)
07/2010 - 10/2002
3Osteonecrosis (Kienbock's Disease)
01/2017 - 03/2010
3Lymphatic Metastasis
10/2015 - 09/2012
3Melanoma (Melanoma, Malignant)
07/2011 - 02/2005
3Metabolic Bone Diseases (Osteopenia)
03/2011 - 08/2006
2Prostatic Neoplasms (Prostate Cancer)
12/2018 - 05/2010
2Squamous Cell Carcinoma of Head and Neck
10/2015 - 09/2012
2Familial Hypophosphatemic Rickets (X-Linked Hypophosphatemia)
01/2011 - 03/2004
2Bisphosphonate-Associated Osteonecrosis of the Jaw
07/2010 - 03/2010
2Hypoxia (Hypoxemia)
05/2007 - 03/2007
2Hyperalgesia
01/2007 - 11/2006
2Ganglion Cysts (Ganglion)
01/2007 - 11/2006
2Osteolysis
11/2006 - 10/2004
2Lung Neoplasms (Lung Cancer)
03/2004 - 03/2002
1Hypertrophy
11/2021
1Hypersensitivity (Allergy)
02/2021
1Osteoporotic Fractures
03/2020
1Tongue Neoplasms (Tongue Neoplasm)
04/2014

Drug/Important Bio-Agent (IBA)

17Diphosphonates (Bisphosphonates)IBA
01/2017 - 10/2002
13DenosumabFDA Link
11/2021 - 06/2011
9AcidsIBA
12/2018 - 04/2006
8LigandsIBA
01/2020 - 08/2004
8Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
10/2013 - 02/2002
8Zoledronic Acid (Zometa)FDA Link
09/2012 - 10/2003
7Proteins (Proteins, Gene)FDA Link
11/2011 - 01/2007
6Messenger RNA (mRNA)IBA
11/2014 - 11/2006
6CytokinesIBA
10/2013 - 08/2003
5Monoclonal AntibodiesIBA
06/2016 - 10/2004
5Protons (Proton)IBA
10/2015 - 11/2006
5Parathyroid Hormone-Related ProteinIBA
06/2011 - 10/2002
4Receptor Activator of Nuclear Factor-kappa B (TRANCE-R)IBA
06/2016 - 08/2004
4Biological ProductsIBA
08/2014 - 03/2005
3Lactic Acid (Lactate)FDA LinkGeneric
01/2022 - 01/2015
3Transcription Factors (Transcription Factor)IBA
11/2021 - 03/2007
3Vascular Endothelial Growth Factor CIBA
10/2015 - 09/2012
3Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
11/2014 - 02/2006
3Dinoprostone (PGE2)FDA Link
11/2014 - 02/2006
3N- (2- cyclohexyloxy- 4- nitrophenyl)methanesulfonamideIBA
11/2014 - 02/2006
3Cyclooxygenase 2 (Cyclooxygenase-2)IBA
04/2014 - 02/2006
3Neutralizing AntibodiesIBA
12/2012 - 08/2011
3Phosphates (Orthophosphate)IBA
07/2010 - 03/2004
3CSK Tyrosine-Protein KinaseIBA
05/2010 - 08/2003
3IntegrinsIBA
10/2004 - 05/2002
3Complementary DNA (cDNA)IBA
10/2003 - 02/2002
2Oxygen (Dioxygen)IBA
01/2022 - 05/2007
2Antirheumatic Agents (DMARD)IBA
11/2021 - 01/2019
2HMGB1 Protein (HMG1)IBA
02/2021 - 10/2020
2Pharmaceutical PreparationsIBA
03/2020 - 10/2013
2Methotrexate (Mexate)FDA LinkGeneric
01/2019 - 06/2016
2Proton Pumps (Proton Pump)IBA
05/2018 - 10/2015
2bafilomycin A1IBA
05/2018 - 11/2006
2Adenosine Triphosphatases (ATPase)IBA
01/2017 - 07/2011
2Bone Density Conservation AgentsIBA
01/2017 - 01/2017
2MineralsIBA
05/2013 - 07/2010
2Tyrosine Kinase InhibitorsIBA
09/2012 - 11/2006
2ErbB Receptors (EGF Receptor)IBA
09/2012 - 05/2007
2Insulin-Like PeptidesIBA
08/2012 - 06/2011
2Acid Sensing Ion ChannelsIBA
05/2011 - 11/2006
2Collagen Type I (Type I Collagen)IBA
03/2011 - 10/2009
2Hormones (Hormone)IBA
05/2010 - 03/2004
2OsteoprotegerinIBA
09/2008 - 11/2006
2Cell Adhesion MoleculesIBA
07/2008 - 05/2002
2Tartrate-Resistant Acid PhosphataseIBA
01/2008 - 02/2005
2CortactinIBA
05/2006 - 01/2006
2Ibandronic Acid (Boniva)FDA Link
02/2006 - 10/2002
2Indicators and Reagents (Reagents)IBA
03/2004 - 10/2002
1Adenosine Triphosphate (ATP)IBA
01/2022
1Therapeutic UsesIBA
10/2021
15-bromo-2'-chloro-2-aminobenzophenoneIBA
02/2021
1DNA-Binding Proteins (DNA Binding Protein)IBA
10/2020
1Histones (Histone)IBA
10/2020
1AndrogensIBA
12/2018
1Analgesics (Analgesic Drugs)IBA
12/2018
1Alkaline PhosphataseIBA
12/2018
1Connexin 43 (Connexin43)IBA
01/2017
1RANK LigandIBA
06/2016
1Notch ReceptorsIBA
03/2016
1Ion Channels (Ion Channel)IBA
10/2015
1Fibronectins (Fibronectin)IBA
10/2015
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
11/2014
1Epidermal Growth Factor (EGF)IBA
09/2012
1StathminIBA
09/2012
1Gefitinib (Iressa)FDA Link
09/2012
1Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
08/2012
1Tyrosine (L-Tyrosine)FDA Link
08/2012
1Insulin-Like Growth Factor I (IGF-1)IBA
08/2012

Therapy/Procedure

6Therapeutics
01/2019 - 08/2003
2Drug Therapy (Chemotherapy)
12/2018 - 06/2011
1Denervation
12/2018
1Castration
12/2018